VIA
ABUS icon

Virtus Investment Advisers’s Arbutus Biopharma ABUS Stock Holding History

Virtus Investment Advisers’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$369K Buy
76,807
+18,912
+33% +$83K 0.09% 328
2026
Q1 		$261K Buy
57,895
+1,412
+2% +$6.17K 0.07% 306
2025
Q4 		$272K Buy
56,483
+24,699
+78% +$111K 0.07% 286
2025
Q3 		$144K Buy
31,784
+5,518
+21% +$20.3K 0.04% 381
2025
Q2 		$81.2K Sell
26,266
-19,848
-43% -$65.9K 0.03% 419
2025
Q1 		$161K Buy
+46,114
New +$154K 0.04% 305

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Virtus Investment Advisers's ABUS Position: Q2 2026 in Review

Virtus Investment Advisers increased its Arbutus Biopharma (ABUS) stake by 33% in Q2 2026, buying an estimated $83K and bringing the position to 76,807 shares worth $369K. The position accounts for 0.09% of the portfolio, ranked #328.

Virtus Investment Advisers first reported a position in ABUS in Q1 2025 and has held it in 6 quarters since. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Virtus Investment Advisers held 76,807 shares of Arbutus Biopharma worth $369K as of Q2 2026.
  • Virtus Investment Advisers bought 18,912 Arbutus Biopharma shares in Q2 2026, an estimated $83K.
  • Arbutus Biopharma made up 0.09% of Virtus Investment Advisers's portfolio in Q2 2026, its #328 holding.
  • Virtus Investment Advisers first reported a position in Arbutus Biopharma in Q1 2025 and has held it in 6 quarters since.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.